
Discovering heterogeneous subpopulations for fine-grained analysis of opioid use and opioid use disorders

Jen J. Gong, Abigail Z. Jacobs, Toby E. Stuart, Mathijs de Vaan
University of California, Berkeley
{jengong, azjacobs, mdevaan, tstuart}@berkeley.edu

Abstract

The opioid epidemic in the United States claims over 40,000 lives per year, and it is estimated that well over two million Americans have an opioid use disorder. Over-prescription and misuse of prescription opioids play an important role in the epidemic. Individuals who are prescribed opioids, and who are diagnosed with opioid use disorder, have diverse underlying health states. Policy interventions targeting prescription opioid use, opioid use disorder, and overdose often fail to account for this variation. To identify latent health states, or *phenotypes*, pertinent to opioid use and opioid use disorders, we use probabilistic topic modeling with medical diagnosis histories from a statewide population of individuals who were prescribed opioids. We demonstrate that our learned phenotypes are predictive of future opioid use-related outcomes. In addition, we show how the learned phenotypes can provide important context for variability in opioid prescriptions. Understanding the heterogeneity in individual health states and in prescription opioid use can help identify policy interventions to address this public health crisis.

1 Introduction

Prescription opioids, such as Vicodin, Percocet, and Oxycontin, are commonly prescribed for chronic and acute pain, and can be effective treatments. However, opioids are highly addictive, opioid use disorders (OUD) have become widespread, and in 2016 alone, the United States saw nearly 45,000 opioid-related drug overdose deaths [1]. While some populations are understood to be vulnerable (e.g., pregnant women, users of injection drugs [14]), existing policy interventions fail to meaningfully account for heterogeneity in patient populations and differences in underlying health status [3, 17]. In order to understand where avenues for effective interventions exist, it is important to accurately characterize variability in opioid use with respect to latent health status.

To address this, we learn *diagnostic phenotypes* of prescription opioid users to understand the heterogeneous underlying health conditions that individuals who are prescribed opioids have. Whereas existing work using machine learning to gain insight into the opioid epidemic has used text-based data mining to identify and analyze non-prescription use of opioids [11] and supervised methods to predict opioid use outcomes in a general population [7], our goal is to identify meaningful latent health states to understand variability in opioid use and opioid use disorders *within* diagnostic phenotypes. We use Latent Dirichlet Allocation (LDA) [6] to learn phenotypes from the diagnostic histories of all individuals who had at least one healthcare episode, filled a prescription opioid, and were not previously diagnosed or treated for an opioid use disorder.

We demonstrate that the learned phenotypes can be used to predict future OUD, long-term use of opioids (>180 days supply annually [4]), and opioid overdose. We also show that the learned phenotypes are associated with differences in opioid prescription filling behavior. Finally, we show how examining variation in filled opioid prescriptions within phenotypes can shed light on differences in opioid use for individuals with and without opioid use disorders.

2 Data

Population-level insurance claims data Our data come from the Massachusetts All Payer Claims Database and capture almost all healthcare interactions from residents of Massachusetts for 2010-2014—a period during which OUD prevalence and opioid overdose deaths more than doubled [12]. By 2015, OUD prevalence in Massachusetts for people over age 11 was 4.6% [5].

The data, collected and provided by the Massachusetts Center for Health Information and Analysis, include medical and pharmacy claims from private and public payers. These data are date-stamped, and include diagnoses, prescriptions and refills, member insurance eligibility information, and more. The data are sparse but longitudinal, spanning up to 5 years for each member.

Inclusion criteria To mitigate the effects of censoring (data before 2010 and after 2014 are unobserved, and data after earliest OUD diagnosis are ignored), we focus on claims from 2011. We use only data from individuals who filled an opioid prescription for oral or transdermal opioids in 2011 [18], had a healthcare visit in 2011, had insurance eligibility prior to 2011, and were not observed to have OUD in 2011 or before. This ensures that each individual has at least one year of diagnostic history, and prevents us from removing too many of the individuals diagnosed with OUD in future years. We identified individuals with OUD based on ICD-9 diagnosis codes for opioid abuse, opioid dependence, opioid abuse or dependence in remission, and opioid poisoning and filled prescriptions for OUD or overdose treatment (buprenorphine, methadone, naloxone). For ease of exposition, we refer to diagnosis and/or treatment of opioid use disorder as OUD in the remainder of the paper.

Data Processing We construct documents describing the diagnostic histories of each individual using a binary representation for whether or not an ICD-9 diagnosis code was assigned at any point in 2011. We use binary occurrences rather than counts, because counts reflect the interaction between utilization of health services attributable to access/tendency to go to the doctor, and utilization attributable to *health state*. A binary representation forces the phenotypes to focus on learning health state from co-occurrence of distinct diagnoses.

The data were divided into a 60/20/20 training/validation/test split, stratified by whether or not the individual was diagnosed or treated for OUD. Diagnosis codes that occurred in fewer than 3 individuals or in more than 99% of individuals in the training data were filtered out. This resulted in approximately 13,000 diagnosis codes in the final vocabulary. Table 1 describes the overall cohort demographics and outcome incidence, as well as the breakdown for the training, validation, and test sets.

Table 1: Cohort demographics and training/validation/test data descriptions.

	N	n_{OUD}	$n_{\text{long-term use}}$	n_{overdose}	Age (%)					Gender, F	Medicaid
					[0, 21]	(21, 44]	(44, 64]	(64, 75]	(75,)	(%)	(%)
Training	1,098,687	33,555 (3.1%)	50,364 (4.6%)	2,874 (0.3%)	13.9	33.5	37.5	12.7	2.3	57.9	19.1
Validation	366,230	11,185 (3.1%)	16,961 (4.6%)	955 (0.3%)	13.8	33.6	37.6	12.6	2.4	57.9	19.0
Test	366,230	11,185 (3.1%)	16,623 (4.5%)	928 (0.3%)	13.9	33.7	37.4	12.7	2.4	57.9	19.1
Overall	1,831,147	55,925 (3.1%)	83,948 (4.6%)	4,757 (0.3%)	13.9	33.6	37.5	12.7	2.4	57.9	19.1

3 Methods

Learning Phenotypes We use the gensim [16] implementation of Latent Dirichlet Allocation [6] (LDA) to learn phenotypes from the diagnostic histories of individuals who were prescribed opioids. Probabilistic topic modeling methods such as LDA have been shown to learn meaningful subtypes from clinical notes [10], clinical order patterns [8], billing codes [9], and multimodal Electronic Health Record data [15]. We use an asymmetric prior on α to account for differences in prevalence of particular conditions. This is similar to how stopwords can be accounted for in text [20]. For each individual, LDA takes as input the set of diagnosis codes and learns *topics (phenotypes)*, where each topic is a distribution over diagnosis codes, and each individual is a distribution over topics.

Predictive Models We train L2-regularized logistic regression models on the training data to predict future opioid use-related outcomes. We incorporate an asymmetric cost parameter to weight examples from the minority class as more important during training, due to the high class imbalance. Values for the regularization parameter and for the asymmetric cost parameter are selected using 5-fold cross-validation on the training set.

Selecting Number of Topics We explore number of topics between 10 and 90 in increments of 5. All topic models are trained using only the training data. Predictive models for OUD are trained using the topic distributions, as described in the previous section. The number of topics that results in the best performance on the validation set is 80 (Figure A1).

Table 2: Diagnostic phenotypes with most and least enrichment for future OUD diagnoses post 2011, with the top 3 ICD-9 diagnosis codes for each phenotype.

Topic	Most Enriched for Future OUD	Topic	Least Enriched for Future OUD
32	Tobacco use disorder, DMII wo cmp nt st unentr, Depressive disorder NEC	29	Routine medical exam, Vaccin for influenza, Scrn malig neop-prostate
59	Alcohol abuse-unspec, Alcoh dep NEC/NOS-unspec, Hpt C w/o hepat coma NOS	3	Sebaceous cyst, Scar & fibrosis of skin, Benign neo skin arm
54	Altered mental status, Muscle weakness-general, Abnormality of gait	45	Senile nuclear cataract, Tear film insuffic NOS, Opn angl brdrln lo risk
4	Post-proc states NEC, Acq absence of organ NEC, Macular degeneration NOS	47	Screen mammogram NEC, Routine gyn examination, Bone & cartilage dis NOS
25	Tobacco use disorder, Long-term use meds NEC, History of tobacco use	78	Other sborheic keratosis, Actinic keratosis, Benign neo skin trunk

Table 2 describes the top 5 and bottom 5 topics by *enrichment* for OUD. The enrichment of topic t for label y is defined as the weighted average of the topic presence for topic t , where the weight is the label y : $\frac{\sum_{i=1}^N t_i y_i}{\sum_{i=1}^N t_i}$ [10, 13]. The full set of topics is described in Table A1. Topics with diagnoses describing other substance use disorders (e.g., alcohol dependence, tobacco use disorder, and long-term use of medications in topics 32, 59, and 25) are highly enriched for OUD. In contrast, topics describing routine exams (e.g., topics 29 and 47) are not highly enriched for OUD. These observations are in accordance with prior knowledge about individuals with OUD [2, 19].

4 Results

Diagnostic phenotypes can predict OUD-related outcomes We demonstrate that our learned phenotypes capture meaningful patient health states relating to opioid use and OUD by predicting three outcomes post-2011 related to opioid use: 1) OUD, 2) long-term opioid use, and 3) opioid overdose. Using these phenotypes, learned from diagnoses alone, we are able to predict future opioid use related outcomes with high AUC (> 0.8). Importantly, we do not use *any* information about prescription medication/opioid use as features in the learning process.

We compare performance against models using demographic information (features described in Table 1) and models combining demographic information with the learned diagnostic phenotypes. Performance on these tasks is shown in Figure 1. 95% confidence intervals were constructed from model performance on 100 stratified, bootstrapped samples of the test set. Improvements in performance using diagnostic phenotypes vs. demographics are statistically significant, as are improvements in performance when adding demographics to diagnostic phenotypes compared to using diagnostic phenotypes alone (paired t -test on bootstrapped samples, $p < 0.001$).




Figure 1: AUCs and 95% confidence intervals using demographic information, diagnostic phenotypes, and both to predict future long-term use, OUD, and overdose.

While these supervised models indicate that diagnostic phenotypes are important in predicting opioid use-related outcomes, the *labels* we use may not be reliable. For example, not all individuals who have OUD are diagnosed or treated for it, and not all opioid overdose events may be recorded in the claims data we are looking at.

Using Diagnostic Phenotypes to Gain Insight Analyses of the unsupervised diagnostic phenotypes can also be used to lend insight into risk factors of OUD and avenues for intervention. As one example, we analyze variation in days supply of opioid prescriptions *within* diagnostic phenotypes.




Figure 2: Enrichment of learned diagnostic phenotypes for days supply of opioids in 2011. Bar height corresponds to expected days supply for that underlying health state. The horizontal line denotes the average days supply of opioid prescriptions (≈ 14 days) in the population we considered.

Figure 2 illustrates each topic’s enrichment for total days supply (calculated as described in Section 3) of opioid prescription fills in 2011. A dashed line is drawn to indicate the average total days supply (14 days) for prescription opioids in 2011. Topics with enrichment values above the line indicate above-average days supply. For example, topics 52 and 14 (back pain, chronic pain), topic 1 (Osteoarthritis, joint replacement), and topic 32 (tobacco use disorder) are highly enriched for days supply. On the other hand, topics 30 (pregnancy) 56 (routine gynecological exam) have lower enrichment for days supply. These enrichment values show that chronic conditions are associated with chronic usage (higher days supply), whereas acute conditions or more routine events are associated with lower than average days supply.




Figure 3: Distribution of the $\log(\text{days supply})$ within diagnostic phenotypes with low enrichment (Topic 30, pregnancy), average enrichment (Topic 42, chronic liver disease), and high enrichment (Topic 52, lower back pain) for total days supply of opioids in 2011.

Figure 3 illustrates the variation in usage and outcomes *within* health status across three topics with low (pregnancy), average (chronic kidney disease) and high (lower back pain) enrichment for days supply of opioids in 2011. Individuals were assigned to the diagnostic phenotype with the highest probability.

This analysis highlights the importance of considering variation within diagnostic groups. While the average total days supply of opioids for individuals assigned to topic 30 (pregnancy) is much lower than the average total days supply for lower back pain, there is considerable variation within those assigned to each specific topic, and there are salient differences in prescription opioid use between those who are diagnosed with or treated for OUD outcomes in the years following (2012-2014), and those who are not.

5 Discussion & Future Work

In this work, we characterize diagnostic phenotypes in individuals who have filled an opioid prescription and have not yet been diagnosed or treated for opioid use disorder or a related outcome. We demonstrate that meaningful phenotypes can be discovered from a year of diagnostic claims data using Latent Dirichlet Allocation, and that these phenotypes are predictive of OUD, long-term use of opioids, and opioid overdose. We additionally show that these learned phenotypes can enable fine-grained analysis of opioid use and opioid use disorders.

There are a number of limitations to and future directions for this work. First, diagnoses capture information relevant to individual health, but procedures and other prescription medication can also help inform our learned phenotypes. Second, by only considering whether or not a diagnosis is present in the year, we remove considerations of health services *utilization* and *access*. But, differences in access and utilization can be potential confounders and we plan to model these characteristics directly. Finally, we present a qualitative illustration of differences in opioid use in individuals who do and do not have an observed future diagnosis of OUD, conditioned on diagnostic phenotype; future work will investigate quantitative differences, and soft groupings (rather than hard assignments) of individuals to phenotypes.

While pathways to addiction, treatment, and addiction recovery are poorly understood, understanding the heterogeneous health states of individuals who are prescribed opioids will generate new understanding of opioid use and opioid use disorders. Furthermore, characterizing this heterogeneity can help us identify vulnerable populations and potential policy levers to address overprescription and misuse of opioids.

References

- [1] F. B. Ahmad, L. M. Rossen, M. R. Spencer, M. Warner, and P. Sutton. Provisional drug overdose death counts, <https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm>. *CDC National Center for Health Statistics*, 2018.
- [2] Ahrnsbrak et al., Substance Abuse and Mental Health Services Administration (SAMHSA). Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health. 2016.
- [3] M. L. Barnett, J. Gray, A. Zink, and A. B. Jena. Coupling policymaking with evaluation—the case of the opioid crisis. *NEJM*, 377(24):2306–2309, 2017.
- [4] M. L. Barnett, A. R. Olenski, and A. B. Jena. Opioid-prescribing patterns of emergency physicians and risk of long-term use. *NEJM*, 376(7):663–673, 2017.
- [5] J. A. Barocas, L. F. White, J. Wang, A. Y. Walley, M. R. LaRochelle, D. Bernson, T. Land, J. R. Morgan, J. H. Samet, and B. P. Linas. Estimated prevalence of opioid use disorder in massachusetts, 2011–2015: A capture–recapture analysis. *American Journal of Public Health*, pages e1–e7, 2018. PMID: 30359112.
- [6] D. M. Blei, A. Y. Ng, and M. I. Jordan. Latent dirichlet allocation. *Journal of Machine Learning Research*, 3:993–1022, 2003.
- [7] Z. Che, J. S. Sauver, H. Liu, and Y. Liu. Deep learning solutions for classifying patients on opioid use. In *AMIA Annual Symposium Proceedings*, volume 2017, page 525. American Medical Informatics Association, 2017.
- [8] J. H. Chen, M. K. Goldstein, S. M. Asch, L. Mackey, and R. B. Altman. Predicting inpatient clinical order patterns with probabilistic topic models vs conventional order sets. *Journal of the American Medical Informatics Association*, 24(3):472–480, 2017.
- [9] Y. Chen, J. Ghosh, C. A. Bejan, C. A. Gunter, S. Gupta, A. Kho, D. Liebovitz, J. Sun, J. Denny, and B. Malin. Building bridges across electronic health record systems through inferred phenotypic topics. *Journal of biomedical informatics*, 55:82–93, 2015.
- [10] M. Ghassemi, T. Naumann, F. Doshi-Velez, N. Brimmer, R. Joshi, A. Rumshisky, and P. Szolovits. Unfolding physiological state: Mortality modelling in intensive care units. In *Proceedings of the 20th ACM SIGKDD international conference on Knowledge discovery and data mining*, pages 75–84. ACM, 2014.

- [11] J. Kalyanam, T. Katsuki, G. R. Lanckriet, and T. K. Mackey. Exploring trends of nonmedical use of prescription drugs and polydrug abuse in the Twittersphere using unsupervised machine learning. *Addictive behaviors*, 65:289–295, 2017.
- [12] MA Dept. of Public Health. An Assessment of Fatal and Nonfatal Opioid Overdoses in Massachusetts (2011–2015), 2017.
- [13] B. M. Marlin, D. C. Kale, R. G. Khemani, and R. C. Wetzel. Unsupervised pattern discovery in electronic health care data using probabilistic clustering models. In *Proceedings of the 2nd ACM SIGHIT International Health Informatics Symposium*, pages 389–398. ACM, 2012.
- [14] E. National Academies of Sciences, Medicine, et al. *Pain management and the opioid epidemic: balancing societal and individual benefits and risks of prescription opioid use*. National Academies Press, 2017.
- [15] R. Pivovarov, A. J. Perotte, E. Grave, J. Angiolillo, C. H. Wiggins, and N. Elhadad. Learning probabilistic phenotypes from heterogeneous ehr data. *Journal of Biomedical Informatics*, 58:156–165, 2015.
- [16] R. Řehůřek and P. Sojka. Gensim—statistical semantics in python. 2011.
- [17] SAMHSA. Using Prescription Drug Monitoring Program Data to Support Prevention Planning, At-A-Glance, <https://www.samhsa.gov/capt/sites/default/files/resources/pdmp-overview.pdf>. 2018.
- [18] M. J. Seamans, T. S. Carey, D. J. Westreich, S. R. Cole, S. B. Wheeler, G. C. Alexander, V. Pate, and M. A. Brookhart. Association of household opioid availability and prescription opioid initiation among household members. *JAMA Internal Medicine*, 178(1):102–109, 2018.
- [19] A. Shah, C. J. Hayes, and B. C. Martin. Characteristics of initial prescription episodes and likelihood of long-term opioid use—United States, 2006–2015. *Morbidity and Mortality Weekly Report*, 66(10):265–269, 2017.
- [20] H. M. Wallach, D. M. Mimno, and A. McCallum. Rethinking LDA: Why priors matter. In *Advances in neural information processing systems*, pages 1973–1981, 2009.

Appendix

Predicting OUD to select number of topics




Figure A1: Change in AUC for predicting opioid use disorder or treatment after 2011 using topics learned from diagnostic histories in 2011. The red line depicts performance on the training set, and the blue line depicts performance on the validation set.

Table A1: Descriptions of learned topics (top 3 ICD-9 diagnosis codes).

Topic	α	Description (Top 3 ICD-9 Codes)
0	0.034	Generalizd hyperhidrosis, Counseling NOS, Non-healing surgcl wound
1	0.070	Osteoarthros NOS-unspec, Joint replaced knee, Aftercare joint replace
2	0.090	Screen lipid disorders, Rhinitis due to pollen, Screen-diabetes mellitus
3	0.069	Sebaceous cyst, Scar & fibrosis of skin, Benign neo skin arm
4	0.043	Post-proc states NEC, Acq absence of organ NEC, Macular degeneration NOS
5	0.174	Eye & vision examination, Myopia, Presbyopia
6	0.072	Dermatophytosis of nail, Pain in limb, Ingrowing nail
7	0.640	Hypertension NOS, Hyperlipidemia NEC/NOS, Pure hypercholesterolem
8	0.097	Palpitations, Overweight, Abnormal weight gain
9	0.079	Carpal tunnel syndrome, Joint pain-hand, Pain in limb
10	0.074	Vaccination for Td-DT, Other specfd counseling, Need prphyl vc vrl hepat
11	0.057	Absence of menstruation, Contraceptive mangmt NEC, Pregnancy test negative
12	0.113	Asthma NOS, Shortness of breath, Respiratory abnorm NEC
13	0.075	Excessive menstruation, Menstrual disorder NEC, Irregular menstruation
14	0.138	Backache NOS, Lumbago, Chronic pain NEC
15	0.103	Diarrhea, Nausea with vomiting, Noninf gastroenterit NEC
16	0.046	Abdmnal pain rt upr quad, Cholelithiasis NOS, Herpes zoster NOS
17	0.055	Calculus of kidney, Abdmnal pain oth specf st, Hydronephrosis
18	0.040	Follow-up exam NEC, Female infertility NOS, Superficial inj cornea
19	0.110	Pain in limb, Joint pain-ankle, Hypermetropia
20	0.202	Acute pharyngitis, Acute uri NOS, Cough
21	0.128	Chest pain NOS, Chest pain NEC, Shortness of breath
22	0.093	Chr airway obstruct NEC, Pneumonia, organism NOS, Other lung disease NEC
23	0.057	Cellulitis NOS, Leukocytosis NOS, Oth nspecf finding blood
24	0.130	Abdmnal pain unspcf site, Constipation NOS, Abdmnal pain oth specf st
25	0.096	Tobacco use disorder, Long-term use meds NEC, History of tobacco use
26	0.080	Lower leg injury NOS, Sprain of ankle NOS, Joint pain-ankle
27	0.154	Dermatitis NOS, Nonspecif skin erupt NEC, Acne NEC
28	0.135	Headache, Migrne unsp wo ntrc mgrn, Skin sensation disturb
29	0.497	Routine medical exam, Vaccin for influenza, Scrn malig neop-prostate
30	0.031	Supervis oth normal preg, Deliver-single liveborn, Preg state, incidental
31	0.141	Acute sinusitis NOS, Allergic rhinitis NOS, Viral infection NOS
32	0.056	Tobacco use disorder, DMII wo cmp nt st uncntr, Depressive disorder NEC

33	0.113	Oth spcf preop exam, Preop cardiovsclr exam, Preop exam unspcf
34	0.059	Enlargement lymph nodes, Observ-suspect cond NEC, Antineoplastic chemo enc
35	0.088	Swelling of limb, Edema, Pain in limb
36	0.108	DMII wo cmp nt st uncntd, DMII wo cmp uncntd, DMII neuro nt st uncntd
37	0.090	Cervicalgia, Cervical spondylosis, Brachial neuritis NOS
38	0.072	Impacted cerumen, Hearing loss NOS, Sensorneur hear loss NOS
39	0.071	BPH w/o urinary obs/LUTS, Elvtd prstate spcf antgn, Malign neopl prostate
40	0.067	Osteoporosis NOS, Pain in thoracic spine, Idiopathic scoliosis
41	0.089	Dizziness and giddiness, Syncope and collapse, Insect bite NEC
42	0.079	Abn blood chemistry NEC, Chronic liver dis NEC, Abn liver function study
43	0.067	Fem genital symptoms NOS, Ovarian cyst NEC/NOS, Uterine leiomyoma NOS
44	0.080	Chronic sinusitis NOS, Nasal & sinus dis NEC, Chronic rhinitis
45	0.128	Senile nuclear cataract, Tear film insuffic NOS, Opn angl brdrln lo risk
46	0.068	Chronic kidney dis NOS, Renal & ureteral dis NOS, Chr kidney dis stage III
47	0.194	Screen mammogram NEC, Routine gyn examination, Bone & cartilage dis NOS
48	0.069	Hypotatsemia, Tachycardia NOS, Hyposmolality
49	0.121	Cor ath unsp vsl ntv/gft, Crnry athrscl natve vsll, Mitral valve disorder
50	0.086	Acute bronchitis, Cough, Impotence, organic origin
51	0.093	Head injury NOS, Pain in limb, Joint pain-up/arm
52	0.095	Lumb/lumbosac disc degen, Lumbago, Lumbosacral spondylosis
53	0.035	Lyme disease, Cellulitis of arm, Follow-up exam NOS
54	0.077	Altered mental status, Muscle weakness-general, Abnormality of gait
55	0.075	Myalgia and myositis NOS, Somat dysfunc lumbar reg, Spasm of muscle
56	0.205	Routine gyn examination, Screen mal neop-cervix, Vaginitis NOS
57	0.038	Disorder of thyroid NOS, Regional enteritis NOS, Ulcerative colitis unspcf
58	0.067	Muscle weakness-general, Abnormality of gait, Convulsions NEC
59	0.065	Alcohol abuse-unspec, Alcoh dep NEC/NOS-unspec, Hpt C w/o hepat coma NOS
60	0.053	Idio periph neurpthy NOS, Mononeuritis NOS, Mal neo bronch/lung NOS
61	0.093	Joint pain-l/leg, Osteoarthros NOS-l/leg, Joint effusion-l/leg
62	0.122	Routin child health exam, Otitis media NOS, Otagia NOS
63	0.116	Obesity NOS, Obstructive sleep apnea, Morbid obesity
64	0.065	Hemorrhoids NOS, Visual disturbances NEC, Rectal & anal hemorrhage
65	0.070	Lump or mass in breast, Malign neopl breast NOS, Hx of breast malignancy
66	0.035	Fam hx-diabetes mellitus, Fam hx-cardiovas dis NEC, Sprain hip & thigh NOS
67	0.061	Long-term use anticoagul, Therapeutic drug monitor, Atrial fibrillation
68	0.042	Local suprficial swelling, Insertion of iud, Iud surveillance
69	0.045	Aftr-catar obscur vision, Local skin infection NOS, Ulcer other part of foot
70	0.086	Esophageal reflux, Gstr/ddnts NOS w/o hmrhg, Diaphragmatic hernia
71	0.139	Urin tract infection NOS, Dysuria, Urinary frequency
72	0.216	Anxiety state NOS, Depressive disorder NEC, Dysthymic disorder
73	0.104	Anemia NOS, Abnormal loss of weight, Iron defic anemia NOS
74	0.047	Prim cardiomyopathy NEC, CHF NOS, Atrial fibrillation
75	0.074	Joint pain-shlder, Rotator cuff synd NOS, Shoulder region dis NEC
76	0.030	Abdmnal pain rt lwr quad, Spondylolisthesis, Acute appendicitis NOS
77	0.108	Screen malig neop-colon, Dvrtclo colon w/o hmrhg, Benign neoplasm lg bowel
78	0.123	Other sborheic keratosis, Actinic keratosis, Benign neo skin trunk
79	0.057	Vaccn/inoc viral dis NEC, Need prphyl vc varicella, Need prphyl vc vrl hepat